The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Know Your Labs

Know Your Labs

February 1, 2009 • By Peter H. Schur, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Because of these considerations, there should be economic savings in employing a solid-phase immunoassay for quantitating an ANA. Thus, in an attempt to develop solid-phase ANA immunoassays, a number of groups have put onto the solid phase whatever antigens are typically assayed in the more specific ANA immunoassays (e.g., DNA, Sm, RNP, Ro/SSA, La/SSB, nucleoprotein, cell extracts, etc.). In published reports, the correlation coefficient between ANA titers and these solid-phase assays is quite good. Thus, many commercial firms have switched their ANAs to these solid-phase immunoassays.4-23 Of concern, however, is the high frequency/percentage of false-negative results in patients with known SLE and related diseases, as well as the continued high frequency of “false positives” (e.g., a positive ANA in someone without SLE) in these studies.15-21 Further work is needed to improve the sensitivity and especially the specificity of these solid-phase immunoassays to ensure that patients with SLE and related diseases are not missed by these solid-phase immunoassays.

You Might Also Like
  • Know Your Labs, Part 2
  • New Study Reveals Limitations in ANA Test Kits for Lupus
  • Insurer Updates
Explore This Issue
February 2009
Also By This Author
  • Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

Table 2: ANA Disease Associations

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version
Table 2: ANA Disease Associations

Antibodies to DNA

Antibodies to DNA can be primarily divided into those that react with single-stranded (ss) DNA and those recognizing dsDNA.24-26

Anti-ssDNA antibodies have been reported in SLE, rheumatoid arthritis, drug-related lupus, healthy relatives of patients with SLE, and, less commonly, in other rheumatic diseases. (See Table 2, p. 17.) Thus, anti-ssDNA has limited usefulness for the diagnosis of SLE or other rheumatic diseases. Anti-ssDNA does not correlate well with disease activity and are therefore not useful for disease management.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Antibodies to dsDNA are most frequently detected by solid-phase immunoassays, but also in some labs by the crithidia IF assay or occasionally the Farr radioimmunoassay. Most hospital and commercial labs do only one. The Farr assay probably has the highest specificity, and lowest sensitivity of the three assays for the diagnosis of SLE, while solid-phase assays have the highest sensitivity and lowest specificity; the crithidia assay falls in between. The Farr assay also has the disadvantage of using radioactive material, which most labs shun, and the crithidia test is very labor intensive. I prefer the ELISA assay for everyday use.

Anti-dsDNA are specific (95%) though not highly sensitive (70%) for SLE, making them very useful for diagnosis when positive.9 (See Table 2, p. 17.) They are occasionally found in other conditions, including rheumatoid arthritis, juvenile arthritis, drug-induced lupus, autoimmune hepatitis, and even in normal persons.

Titers of anti-dsDNA antibodies often fluctuate with disease activity, especially lupus nephritis, and are therefore useful in many patients for following the course of SLE. If a patient has a rising titer, or very high titer, but clinically is quiescent, I do not treat the serological abnormality, but consider it a warning sign that the patient needs to be followed more closely and treated when something happens clinically to warrant a change in therapy. However, some investigators have treated these serological abnormalities (especially when associated with low complement levels) and have reported improved clinical outcomes. Conversely, I use a falling titer in someone who is getting better after a flare on treatment as a guide in reducing treatment (e.g., corticosteroids and/or immunosuppressives).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Scleroderma, SLE (Lupus) Tagged With: connective tissue disease, Diagnosis, Systemic lupus erythematosus, TestingIssue: February 2009

You Might Also Like:
  • Know Your Labs, Part 2
  • New Study Reveals Limitations in ANA Test Kits for Lupus
  • Insurer Updates
  • Some Lupus Tests Yield False Results

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.